Rate My Professor James Wason

Professor Wason contributes statistically to numerous impactful clinical studies. Key recent publications include 'Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial' in The Lancet Healthy Longevity (2025), 'Mentalisation-based treatment for antisocial personality disorder in males convicted of an offence on community probation in England and Wales (Mentalization for Offending Adult Males, MOAM): a multicentre, assessor-blinded, randomised controlled trial' in The Lancet Psychiatry (2025), 'COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls' in the American Journal of Gastroenterology (2025), and 'Cognitive behavioural therapy skills using a smartphone app for subthreshold depression among adults in the community: the RESiLIENT randomised controlled trial' in Nature Medicine (2025). Additional significant works are 'Efficient stage-wise allocation ratios in multi-arm multi-stage designs' in Contemporary Clinical Trials (2025), 'Utilising high-dimensional data in randomised clinical trials: a review of methods and practice' in Research Methods in Medicine & Health Sciences (2024), 'Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial' in Pulmonary Circulation (2024), 'Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves' disease' in BMJ Open (2024), and 'Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions' in BMJ Open (2024). These contributions have notably advanced clinical trial design in precision medicine, rare diseases, and complex patient populations.